M. Hoeper (Hannover, Germany), M. Humbert (Paris, France)
Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial
O. Sitbon (Paris, France), J. Bosch (Barcelona, Spain), E. Cottreel (Allschwil, Switzerland), P. De Groote (Lille, France), M. Hoeper (Hannover, Germany), M. Krowka (Rochester, United States of America), N. Martin (Allschwil, Switzerland), L. Savale (Paris, France), N. Kim (La Jolla, United States of America)
|     |
Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
O. Sitbon (Paris, France), K. Chin (Texas, United States of America), R. Channick (Massachusetts, United States of America), L. Di Scala (Allschwil, Switzerland), S. Gaine (Dublin, Ireland), H. Ghofrani (London, United Kingdom), I. Lang (Vienna, Austria), V. Mclaughlin (Michigan, United States of America), R. Preiss (Allschwil, Switzerland), L. Rubin (California, United States of America), G. Simonneau (Paris, France), V. Tapson (California, United States of America), N. Galiè (Bologna, Italy), M. Hoeper (Hannover, Germany)
| |
Early improvements predict outcomes in pulmonary arterial hypertension
R. White (Rochester Medical Center, United States of America), C. Vizza (Rome, Italy), C. Blair (Foster City, United States of America), J. Langley (Brentford, United Kingdom), M. Hoeper (Hannover, Germany)
| |
ESC/ERS low-risk profile achievement accurately predicts mortality in scleroderma-associated PAH
V. Mercurio (Baltimore, United States of America), N. Diab (Ottawa, Canada), G. Peloquin (Baltimore, United States of America), T. Housten-Harris (Baltimore, United States of America), R. Damico (Baltimore, United States of America), T. Kolb (Baltimore, United States of America), S. Mathai (Baltimore, United States of America), P. Hassoun (Baltimore, United States of America)
| |
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH)
A. Boucly (Le Kremlin Bicêtre, France), L. Savale (Le Kremlin Bicêtre, France), J. Weatherald (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), X. Jaïs (Le Kremlin Bicêtre, France), G. Simonneau (Le Kremlin Bicêtre, France), M. Humbert (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France)
| |
Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study
Z. PAN (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), N. Blank (Heidelberg, Germany), H. Lorenz (Heidelberg, Germany), C. Fiehn (Baden-Baden, Germany), J. Song (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), A. Marra (Naples, Italy), C. Fischer (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
| |
emPHasis-10 score predicts mortality in patients with pulmonary hypertension
S. Wort (London, United Kingdom), C. Favoccia (London, United Kingdom), A. Kempny (London, United Kingdom), L. Price (London, United Kingdom), C. Mccabe (London, United Kingdom), K. Dimopoulos (London, United Kingdom)
| |
Pirfenidone protects against pulmonary hypertension in the Sugen5416/hypoxia rat model
P. Poble (Le Plessis-Robinson, France), C. Phan (Le Plessis-Robinson, France), T. Quatremare (Le Plessis-Robinson, France), J. Bordenave (Le Plessis-Robinson, France), R. Thuillet (Le Plessis-Robinson, France), A. Cumont (Le Plessis-Robinson, France), A. Huertas (Le Plessis-Robinson, France), P. Dorfmüller (Le Plessis-Robinson, France), L. Tu (Le Plessis-Robinson, France), M. Humbert (Le Plessis-Robinson, France), M. Ghigna (Le Plessis-Robinson, France), C. Guignabert (Le Plessis-Robinson, France)
| |